Patient Segregation in Heart Failure with Preserved Ejection Fraction

A persistent problem remains a challenge in HFpEF - patient heterogeneity.
We need the right patients for the right treatment, but how do we get it to them? We believe one approach to solving this issue is to improve patient segregation and endotyping.
In collaboration with BMS and UPenn, we have recently identified a subset of patients with a very high risk of adverse outcomes, all determined by increased fibroblast activity. We can quantify this risk profile accurately using our PRO-C6 biomarker assay, separating patients according to how likely they are to experience re-hospitalization for HF or all-cause mortality.
These findings were recently published in NEJM Evidence.
So how do we go about handling patient heterogeneity? We believe the time is right to give doctors and clinicians a better tool at hand than what is available now. This is endotrophin endotyping, HF risk stratification redefined.
You can find the article and more here: www.nordicbioscience.com/land...
Article: evidence.nejm.org/doi/full/10...